Logo
Please rotate your device

Landscape orientation recommended.

Menu

No results found.

2607
Shanghai Pharmaceuticals Holding Co., Ltd – HKG
Weekly Share Price & Valuation Overview
Market Overview
Open
12.5000
Close
12.5700
High
12.5800
Low
12.4200
Trend
0.59906

Shanghai Pharmaceuticals Holding Co., Ltd

China • HKG - Hong Kong Stock Exchange • 2607 • Currency: HKD

Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemical and biological drugs, Chinese medicine, health care products, and medical devices to treat immunology, psychiatric and neurological, tumor, cardiovascular, digestive metabolism, psychoneurotic, neoplasm, respiratory system, and anti-infection diseases, as well as invests in equity. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it engages in the operation of a network of retail pharmacy stores. The company was incorporated in 1994 and is headquartered in Shanghai, China.

Key strengths
  • High gross margin (≥35%) suggests strong pricing power or cost control.
  • Quick ratio ≥1.0 indicates obligations can be met without inventory.
Potential weaknesses
  • Debt/EBITDA >4 — elevated leverage vs earnings capacity.
Scale & Structure Core size and share structure. TTM values unless noted. “Estimated” where reconciled from per-share × shares. Revenue estimated from Revenue/share × Shares.
Market Cap Total equity value of the company (share price × shares outstanding).
HKD 68.93B
Enterprise Value Operating value: market cap + total debt − cash.
HKD 73.88B
Total Revenue (TTM) Estimated Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
HKD 68.31B
Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
HKD 29.64B
EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
HKD 10.12B
Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
HKD 74.32
EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
1.28
Dividend Yield Annual dividend ÷ share price. Reconciled using dividend per share when available.
6.64%
Shares Outstanding
919.07M
Float Shares
1.58B
Implied Shares Outstanding
5.42B
Profitability & Efficiency TTM basis. “Reconciled” = numerator ÷ TTM revenue. Margins reflect latest TTM calculations.
Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
3.22%
EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
14.82%
Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
43.40%
Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
1.57%
ROA Return on assets: net income ÷ total assets.
2.42%
ROE Return on equity: net income ÷ shareholder equity.
6.74%
Growth Growth rates are YoY unless labeled QoQ.
Revenue Growth Year-over-year revenue growth.
0.90%
Earnings Growth (YoY) Year-over-year earnings growth.
-14.30%
Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-13.60%
Liquidity & Solvency Balance-sheet health. Debt metrics shown as latest ratios; D/E is a ratio (not %).
Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
1.04
Debt to Equity Total debt ÷ shareholder equity; leverage.
0.70
Total Cash Cash and equivalents.
HKD 45.03B
Total Debt Short + long-term interest-bearing debt.
HKD 59.45B
Net Debt Total debt − cash (negative = net cash).
HKD 14.42B
Debt / EBITDA Leverage relative to operating earnings; lower is safer.
5.87
Cash Flow Shown only when internally consistent; margins are TTM.
Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
HKD 9.10B
Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
HKD 3.87B
OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
13.32%
FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
5.66%
Cash Conversion (OpCF/EBITDA)
0.90
Sharemaestro House View
Risk: 2 Sharemaestro internal risk profile (0–3, higher is safer). Operational: 2 Operational quality/consistency (0–3, higher is better). Composite Score: 1 Overall internal composite (0–3, higher is better). Suggested Allocation: 1.67% Indicative portfolio weighting suggestion based on house view.
Structural Insights (experimental)
Ownership & Liquidity
Free Float Proportion of shares available for public trading.
Insiders Shares held by company insiders (officers, directors). 32.0%
Institutions Shares held by institutions (funds, pensions). 20.9%
Capital Structure
Potential Dilution Increase in share count if options/convertibles exercise.
489.6%
Net Debt Total debt − cash (negative = net cash).
HKD 14.42B
21.1% of revenue Net debt relative to revenue — debt load vs business scale.
Resilience Score 0–100 composite of liquidity, leverage and cash conversion; higher is better. If inputs are unavailable, we estimate using proxies (Net debt vs revenue, Cash-to-Debt). It is a guide, not a rating. 31
Methodology Notes
  • Total Revenue (TTM) estimated from Revenue per Share × Shares due to feed inconsistency.
  • Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
  • Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
As of: 2025-08-18 10:17

Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.

AI generated insights not available yet. Sign in to generate the snapshot.